PositiveID Corp. has submitted to the Food and Drug Administration a 510(k) pre-market notification application for its "iglucose" technology to better manage diabetes. FDA 510(k) clearance is necessary before the product can be commercially available.

The iglucose product enables the transmission of readings from a data-capable glucometer to a diabetes management Web portal where diabetics can gather and track their glucose levels and permit access to family members, caregivers and clinicians. The product eliminates the keeping of paper-based logbooks and helps increase self-management, according to the Delray Beach, Fla.-based vendor.

In addition to iglucose, the company continues development of a breath glucose detection device and an implantable glucose-sensing microchip. More information is available at iglucose.com.


Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access